Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2026-10-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with
chemotherapy in patients with recurrent or advanced endometrial cancer. The primary objective
is to evaluate objective response rate of cadonilimab plus chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Cancer Hospital
Collaborators:
Fujian Provincial Hospital The First Affiliated Hospital of Bengbu Medical University The First Affiliated Hospital of Nanchang University Zhangzhou Affiliated Hospital of Fujian Medical University